Historical Valuation
Integra Lifesciences Holdings Corp (IART) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.04 is considered Undervalued compared with the five-year average of 14.18. The fair price of Integra Lifesciences Holdings Corp (IART) is between 48.58 to 73.36 according to relative valuation methord. Compared to the current price of 13.51 USD , Integra Lifesciences Holdings Corp is Undervalued By 72.19%.
Relative Value
Fair Zone
48.58-73.36
Current Price：13.51
72.19%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Integra Lifesciences Holdings Corp (IART) has a current Price-to-Book (P/B) ratio of 0.90. Compared to its 3-year average P/B ratio of 1.54 , the current P/B ratio is approximately -41.36% higher. Relative to its 5-year average P/B ratio of 2.24, the current P/B ratio is about -59.82% higher. Integra Lifesciences Holdings Corp (IART) has a Forward Free Cash Flow (FCF) yield of approximately -0.48%. Compared to its 3-year average FCF yield of 2.19%, the current FCF yield is approximately -122.06% lower. Relative to its 5-year average FCF yield of 3.11% , the current FCF yield is about -115.54% lower.
P/B
Median3y
1.54
Median5y
2.24
FCF Yield
Median3y
2.19
Median5y
3.11
Competitors Valuation Multiple
AI Analysis for IART
The average P/S ratio for IART competitors is 65.27, providing a benchmark for relative valuation. Integra Lifesciences Holdings Corp Corp (IART.O) exhibits a P/S ratio of 0.56, which is -99.14% above the industry average. Given its robust revenue growth of 5.57%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IART
1Y
3Y
5Y
Market capitalization of IART increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IART in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IART currently overvalued or undervalued?
Integra Lifesciences Holdings Corp (IART) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.04 is considered Undervalued compared with the five-year average of 14.18. The fair price of Integra Lifesciences Holdings Corp (IART) is between 48.58 to 73.36 according to relative valuation methord. Compared to the current price of 13.51 USD , Integra Lifesciences Holdings Corp is Undervalued By 72.19% .
What is Integra Lifesciences Holdings Corp (IART) fair value?
IART's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Integra Lifesciences Holdings Corp (IART) is between 48.58 to 73.36 according to relative valuation methord.
How does IART's valuation metrics compare to the industry average?
The average P/S ratio for IART's competitors is 65.27, providing a benchmark for relative valuation. Integra Lifesciences Holdings Corp Corp (IART) exhibits a P/S ratio of 0.56, which is -99.14% above the industry average. Given its robust revenue growth of 5.57%, this premium appears unsustainable.
What is the current P/B ratio for Integra Lifesciences Holdings Corp (IART) as of Jan 09 2026?
As of Jan 09 2026, Integra Lifesciences Holdings Corp (IART) has a P/B ratio of 0.90. This indicates that the market values IART at 0.90 times its book value.
What is the current FCF Yield for Integra Lifesciences Holdings Corp (IART) as of Jan 09 2026?
As of Jan 09 2026, Integra Lifesciences Holdings Corp (IART) has a FCF Yield of -0.48%. This means that for every dollar of Integra Lifesciences Holdings Corp’s market capitalization, the company generates -0.48 cents in free cash flow.
What is the current Forward P/E ratio for Integra Lifesciences Holdings Corp (IART) as of Jan 09 2026?
As of Jan 09 2026, Integra Lifesciences Holdings Corp (IART) has a Forward P/E ratio of 5.04. This means the market is willing to pay $5.04 for every dollar of Integra Lifesciences Holdings Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Integra Lifesciences Holdings Corp (IART) as of Jan 09 2026?
As of Jan 09 2026, Integra Lifesciences Holdings Corp (IART) has a Forward P/S ratio of 0.56. This means the market is valuing IART at $0.56 for every dollar of expected revenue over the next 12 months.